CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION
Clinical trials for CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION explained in plain language.
Never miss a new study
Get alerted when new CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION trials appear
Sign up with your email to follow new studies for CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial aims to outsmart superbug in ICU patients
Disease control Recruiting nowThis study tests three different antibiotic combinations to treat a dangerous, drug-resistant bacteria called CRAB that causes infections in intensive care patients. Researchers will compare colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline in 108 su…
Matched conditions: CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION
Phase: PHASE4 • Sponsor: Clinical Hospital Centre Zagreb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibiotic under the microscope: can it beat superbug infections?
Knowledge-focused Recruiting nowThis study is observing 200 hospitalized adults with carbapenem-resistant Acinetobacter baumannii (CRAB) infections—a type of superbug—who are treated with the antibiotic sulbactam-durlobactam. Researchers will compare their outcomes to patients receiving other treatments to see …
Matched conditions: CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION
Sponsor: Sichuan Provincial People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC